Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (231-240 of 539) with videos related to

Pageof 54
Sort By:
Cancer Discovery|April 25, 2013
Targeting the BRAF V600E mutation in multiple myelomaMindaugas Andrulis, Nicola Lehners, David Capper, et al.
Haematologica|March 12, 2010
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben, Anna Jauch, Uta Bertsch, et al.
International Journal of Cancer|September 9, 2014
T cell-based targeted immunotherapies for patients with multiple myelomaLei Wang, Nan Jin, Anita Schmitt, et al.
Leukemia & Lymphoma|June 2, 2020
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effectsLina Jansen, Maximilian Merz, Monika Engelhardt, et al.
Genes, Chromosomes & Cancer|July 8, 2005
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogeneticsFriedrich W Cremer, Jelena Bila, Isabelle Buck, et al.
Leukemia & Lymphoma|February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaJeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Experimental Hematology|July 26, 2006
The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristicsStefan Fruehauf, Timon Seeger, Patrick Maier, et al.
British Journal of Haematology|June 5, 2007
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growthMichel Jourdan, Jérôme Moreaux, John De Vos, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 21, 2025
Correction to: Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [<sup>18</sup>F]FDG PET/CT predicts survival in multiple myelomaChristos Sachpekidis, Olof Enqvist, Johannes Ulén, et al.
Transfusion|August 14, 2014
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myelomaJian Cheng, Michael Schmitt, Patrick Wuchter, et al.
Pageof 54

Showing results (231-240 of 539) with videos related to

Sort By:
Pageof 54
Cancer Discovery|April 25, 2013
Targeting the BRAF V600E mutation in multiple myelomaMindaugas Andrulis, Nicola Lehners, David Capper, et al.
Haematologica|March 12, 2010
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben, Anna Jauch, Uta Bertsch, et al.
International Journal of Cancer|September 9, 2014
T cell-based targeted immunotherapies for patients with multiple myelomaLei Wang, Nan Jin, Anita Schmitt, et al.
Leukemia & Lymphoma|June 2, 2020
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effectsLina Jansen, Maximilian Merz, Monika Engelhardt, et al.
Genes, Chromosomes & Cancer|July 8, 2005
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogeneticsFriedrich W Cremer, Jelena Bila, Isabelle Buck, et al.
Leukemia & Lymphoma|February 1, 2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaJeffrey L Wolf, David Siegel, Hartmut Goldschmidt, et al.
Experimental Hematology|July 26, 2006
The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristicsStefan Fruehauf, Timon Seeger, Patrick Maier, et al.
British Journal of Haematology|June 5, 2007
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growthMichel Jourdan, Jérôme Moreaux, John De Vos, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 21, 2025
Correction to: Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [<sup>18</sup>F]FDG PET/CT predicts survival in multiple myelomaChristos Sachpekidis, Olof Enqvist, Johannes Ulén, et al.
Transfusion|August 14, 2014
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myelomaJian Cheng, Michael Schmitt, Patrick Wuchter, et al.
Pageof 54